- Home
- BIVI vs BOLT Comparison
BIVI vs BOLT Comparison
Compare BIVI & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- BOLT
- Stock Information
- Founded
- BIVI 2013
- BOLT 2015
- Country
- BIVI United States
- BOLT United States
- Employees
- BIVI N/A
- BOLT N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- BOLT Health Care
- Exchange
- BIVI Nasdaq
- BOLT Nasdaq
- Market Cap
- BIVI 18.8M
- BOLT 16.8M
- IPO Year
- BIVI N/A
- BOLT 2021
- Fundamental
- Price
- BIVI $0.85
- BOLT $0.36
- Analyst Decision
- BIVI Strong Buy
- BOLT Hold
- Analyst Count
- BIVI 1
- BOLT 5
- Target Price
- BIVI $30.00
- BOLT $1.13
- AVG Volume (30 Days)
- BIVI 204.2K
- BOLT 145.0K
- Earning Date
- BIVI 05-13-2025
- BOLT 05-13-2025
- Dividend Yield
- BIVI N/A
- BOLT N/A
- EPS Growth
- BIVI N/A
- BOLT N/A
- EPS
- BIVI N/A
- BOLT N/A
- Revenue
- BIVI N/A
- BOLT $7,690,000.00
- Revenue This Year
- BIVI N/A
- BOLT N/A
- Revenue Next Year
- BIVI N/A
- BOLT $77.45
- P/E Ratio
- BIVI N/A
- BOLT N/A
- Revenue Growth
- BIVI N/A
- BOLT N/A
- 52 Week Low
- BIVI $0.62
- BOLT $0.30
- 52 Week High
- BIVI $7.50
- BOLT $1.34
- Technical
- Relative Strength Index (RSI)
- BIVI 43.28
- BOLT 52.37
- Support Level
- BIVI $0.75
- BOLT $0.33
- Resistance Level
- BIVI $0.88
- BOLT $0.39
- Average True Range (ATR)
- BIVI 0.11
- BOLT 0.04
- MACD
- BIVI 0.02
- BOLT 0.01
- Stochastic Oscillator
- BIVI 81.78
- BOLT 90.00
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.